Mianserin


Tetracyclic alpha-2 adrenergic antagonist

A first-generation tetracyclic antidepressant; the structural and mechanistic precursor to mirtazapine.

Abstract

Mianserin (1,2,3,4,10,14b-hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-a]azepine; CAS 24219-97-4; molecular formula C18H20N2; molecular weight 264.37) is a tetracyclic antidepressant developed at Organon in the 1960s and marketed in Europe and Asia from 1976 (never FDA approved for the US market). The compound is the structural and mechanistic precursor to mirtazapine, sharing the alpha-2 adrenergic auto/heteroreceptor antagonism that increases monoaminergic release. Mianserin additionally exhibits 5-HT2A, 5-HT2C, H1, and alpha-1 antagonism but with a less favorable receptor selectivity profile than mirtazapine. Notable for a higher incidence of agranulocytosis and aplastic anemia than mirtazapine (estimated 1 in 1500 to 1 in 5000 cases) which contributed to its replacement in clinical practice. Plasma half-life is 21 to 61 hours; metabolism is via CYP2D6 with active demethyl-mianserin metabolite. Used as a reference tetracyclic and alpha-2 antagonist in mechanism studies; less common in clinical use today owing to mirtazapine availability.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph